SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing intense selling pressure as investors grapple with concerns over the company's significant debt load, capital expenditure for AI data centers, and a recent credit rating downgrade. While the community is sharply divided, with some investors viewing the current price as a deep-value opportunity based on the massive contract backlog, others fear the heavy leverage and potential for further downside if growth targets are not met.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio is experiencing significant volatility and trading activity following the announcement of a common stock offering, which has divided market participants between those reacting to dilution and those focused on the stock's clinical potential. The community is heavily debating the company's long-term valuation and future clinical readouts while actively tracking technical breakout levels and potential short-squeeze scenarios.

Factorial Energy, Inc. engages in the development and commercialization of solid-state battery technologies. Its platforms include FEST and Solstice, designed to deliver high-performance, scalable battery solutions for applications in drones, robotics, automotive, and other advanced mobility sectors. The company is headquartered in Billerica, MA.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy Inc

Factorial Energy is experiencing high volatility as investors react to a new strategic partnership with Tulip Tech aimed at accelerating solid-state battery deployment for drones. While some in the community view the dip as an overreaction to the recent announcement, others are concerned about potential insider selling and long-term liquidity risks following the company's recent SPAC debut.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is in the spotlight as investors digest its latest quarterly results, which featured earnings and revenue beats driven by robust gains in fixed income trading. Market participants are actively discussing the bank's profitability targets alongside broader sector headwinds, including potential legislative pressure on credit card interest rates and the bank's ongoing strategic reorganization.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick Mining is capturing significant market attention as investors weigh the company's dual-commodity exposure to gold and copper against ongoing operational risks and geopolitical headwinds. The community is actively discussing the potential impact of share buybacks and the anticipated North American IPO as catalysts to unlock shareholder value amid a broader commodities supercycle.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending as investors focus on the potential for European regulatory approval of Miplyffa, with the community actively tracking the upcoming EMA plenary agenda for a breakthrough. Sentiment is bolstered by bullish analyst upgrades and institutional interest, while discussions center on the stock's tight float and the strategic value of the drug's exclusivity protections.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The GDX gold mining ETF is seeing renewed investor interest as community sentiment shifts, driven by central bank buying of physical gold and expectations that monetary policy will need to accommodate massive government debt. Traders are closely monitoring technical support levels while debating whether the current environment of high inflation and geopolitical tension signals a long-term structural breakout for the precious metals sector.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is trending as investors focus on upcoming clinical trial data and the company's platform potential in treating solid tumors. The community is actively discussing the synergistic promise of the Alpha DaRT technology when combined with Merck's Keytruda, fueling bullish sentiment ahead of key presentations and data readouts.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is currently trending as speculation intensifies regarding potential biotech acquisitions intended to bolster its oncology pipeline ahead of the looming patent cliff for Keytruda. The investor community is actively debating the likelihood of a buyout for companies like Sellas Life Sciences and Inhibrx, as Merck seeks to secure innovative cancer platforms to maintain its market dominance.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin shares are experiencing significant volatility as investors weigh concerns about slowing e-commerce growth against bullish analyst reiterations of a Buy rating. The community is actively debating whether recent price swings are driven by institutional manipulation or genuine fundamental shifts in the company's ad-tech platform.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Incyte Says Early Data Points To Promise For Once-Monthly Preventive Treatment For Inherited Blood Disorder

Incyte reports Phase 1/2 latarcibart data showing lower bleeding rates and favorable safety in patients with von Willebrand disease.read more...

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, investigational monoclonal antibody for patients with von Willebrand disease (VWD). The data are being...

Incyte to Report Second Quarter Financial Results

Incyte (Nasdaq:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and conference call/webcast is as follows: Q2 2026 Press Release: July 28, 2026, at 7:00 a.m. ET...

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Incyte (Nasdaq:INCY) announced today it has completed its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC. The acquisition adds VGA039, a novel monoclonal antibody in Phase 3 development for von Willebrand disease (VWD), the most common inherited bleeding...

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.

Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?

Incyte (INCY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

A breakout could be in the cards for this biopharmaceutical play, says Carter Worth

Shares of Incyte are now moving out of a seven-month range...

Incyte Announces Positive CHMP Opinion for Opzelura (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients...

Incyte's Minjuvi Approved In Japan For Relapsed Or Refractory DLBCL

(RTTNews) - Incyte Biosciences (INCY) in Japan announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL...

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

Incyte’s Drug Approved In Europe For Treating Yet Another Rare Cancer 

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

INCYIncyte Corp.

Fundamentals

Latest INCY News